metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet]
metformin hydrochloride
RxCUI: 2677162
What the CMS Formulary Data Shows for metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet]
Per the CMS 2026 Part D formulary file, metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet] (RxNorm concept RXCUI 2677162, generic name metformin hydrochloride) appears on 1 distinct formulary file spanning 4 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 3 to Tier 3, with a cross-plan average of Tier 3.
Real-world access to metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 5,918,026 Part D beneficiaries filled metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet] in 2023, with total plan-and-beneficiary spending of $247,531,906 and an average per-beneficiary annual cost of $41.83. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 4
- Coverage rate
- 0.1%
- Tier range
- Tier 3, Preferred Brand
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 5,918,026
- Total spending
- $247,531,906
- Avg per beneficiary
- $41.83
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet]
4 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Health New England Medicare Compass (PPO) | HEALTH NEW ENGLAND, INC. | T3 | No | $0 | MA |
| Health New England Medicare Value (HMO) | HEALTH NEW ENGLAND, INC. | T3 | No | $0 | MA |
| Health New England Medicare Premium (HMO) | HEALTH NEW ENGLAND, INC. | T3 | No | $15.80 | MA |
| Health New England Medicare Plus (HMO) | HEALTH NEW ENGLAND, INC. | T3 | No | $58.40 | MA |
Frequently Asked Questions
Is metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet] covered by Medicare Part D?
Yes, metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet] is covered by 4 Medicare Part D plans (0.1% of all Part D formularies).
What tier is metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet] on Medicare Part D plans?
metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet] averages Tier 3 across Part D plans, ranging from Tier 3 to Tier 3.
Does metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet] require prior authorization?
0% of Part D formularies require prior authorization for metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet]?
In 2023, total Medicare Part D spending on metformin hydrochloride 1000 MG / sitagliptin 50 MG Oral Tablet [Zituvimet] was $247,531,906, covering 5,918,026 beneficiaries. The average spend per beneficiary was $41.83.
Read our methodology - how this data is sourced, computed, and verified.